SUBMISSION PLANNING SERVICES
BioBoston CRO provides regulatory submission planning services for sponsors that need to convert an approved regulatory pathway into a controlled application plan. Support can include application sequencing, content inventory, readiness assessment, responsibility mapping, dependency management, governance, and preparation oversight for an IND, IDE, 510(k), De Novo, PMA, NDA, BLA, supplement, amendment, or other defined filing.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.
Translate the pathway and evidence strategy into a content inventory, responsibility model, integrated schedule, review process, and readiness criteria.
Create one source of truth for clinical, nonclinical, CMC, quality, safety, statistical, writing, publishing, and regulatory dependencies.
Assess missing decisions, content gaps, unresolved comments, data and document dependencies, ownership, and schedule realism before resetting the plan.
when needed
Problems
The service is most valuable when the team can identify the specific control gap, decision, deliverable, or
recovery need rather than requesting generic capacity.
Scope
The exact scope depends on the maturity of the work, the quality of the inputs, the sponsor’s procedures,
the review model, and the target milestone.
Deliverables
Deliverables should be confirmed at kickoff and linked to defined sponsor decisions, review cycles, and downstream handoffs.
Client inputs
The sponsor does not need every detail finalized before kickoff, but approved decisions, open questions, source owners, reviewers, and deadlines must be distinguishable.
Process
1. Confirm the purpose, current state, intended use, milestone, stakeholders, responsibilities, systems or vendors, and agreed deliverables.
2. Review available source materials, prior decisions, procedures, evidence, and open issues; issue a focused gap and dependency list.
3. Develop the work plan, specifications, document, assessment, or control package included in scope.
4. Coordinate review through named sponsor and cross-functional decision owners and maintain a controlled open-item and comment process.
5. Perform the agreed technical, quality, consistency, or operational checks and document remaining risks or limitations.
6. Prepare the approved handoff, implementation, submission, remediation, archive, or next-step package as defined in scope.
Considerations
The work should remain proportionate to the risk and intended use, follow the sponsor’s controlled process, and preserve clear sponsor decision authority.
Engagement options
BioBoston leads the defined scope from assessment and planning through drafting or execution, review, quality control, and handoff.
BioBoston addresses a specific section, decision, backlog, finding, vendor issue, or stalled deliverable without expanding the engagement unnecessarily.
BioBoston provides an objective second-line review, oversight role, or embedded specialist while the sponsor or another vendor retains primary execution.
RELATED SERVICES
Author the documents and Common Technical Document modules defined by the approved submission plan.
Establish classification, pathway options, authority strategy, evidence implications, and route-to-market decisions before detailed planning.
Plan and develop integrated safety, efficacy, performance, or clinical-evidence summaries as defined by the application.
Coordinate milestones, dependencies, vendors, risks, decisions, budgets, and escalation across the broader program.
Expertise
Submission-planning experience should match the application type, product, development stage, jurisdiction, evidence complexity, functional interfaces, publishing model, and target milestone.
RESOURCES
Explore the following resources for additional insights and information relevant to this service.
A planned checklist covering pathway, evidence, content, sources, data cutoffs, owners, reviews, approvals, publishing, and filing dependencies.
A planned working tool for documents, modules, owners, sources, status, review cycles, dependencies, and approval criteria.
A planned guide to evidence, analyses, reports, authoring, review, publishing, governance, and schedule risk.
FAQs
Typical scope may include strategy and sequence, content inventory, readiness assessment, integrated schedule, responsibilities, dependencies, governance, review planning, risk management, and preparation oversight. The exact application and workstreams must be defined.
Submission Planning owns strategy, sequencing, readiness, content planning, responsibilities, and application management. Submission Writing owns development of the documents and modules defined by that plan.
Yes. A readiness assessment can evaluate approved pathway decisions, evidence, analyses, source documents, content status, ownership, reviews, publishing inputs, dependencies, risks, and schedule assumptions.
BioBoston can provide a defined planning and coordination role. The exact leadership, authoring, publishing, system access, sponsor representation, and filing responsibilities must be confirmed in scope
Meeting strategy and preparation may be coordinated when relevant. FDA Briefing Book Writing owns the meeting-package authoring intent, while Regulatory Affairs retains meeting strategy and regulatory interaction planning.
No. BioBoston can improve planning, traceability, coordination, and readiness, but the sponsor owns its application and authorities determine filing and review outcomes.
PROJECT FORM
Share the application type, jurisdiction, planned milestone, evidence and document status, functional owners, vendors, and principal readiness concerns. A BioBoston team member will review the request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A productive first discussion identifies the pathway, application, evidence status, content inventory, owners, vendors, review model, publishing interface, risks, and target milestone. BioBoston can then define the planning, readiness, and coordination scope.
